Dyne Therapeutics Inc (DYN)

Apr 30, 2026

Dyne therapeutics director Jason Rhodes sells $4.18m in stock By Investing.com - Investing.com Australia

Apr 30, 2026

Apr 30, 2026

Dyne therapeutics director Jason Rhodes sells $4.18m in stock - Investing.com

Apr 30, 2026

Apr 30, 2026

Atlas Venture funds tied to Dyne (DYN) director sell 227,337 shares - Stock Titan

Apr 30, 2026

Apr 30, 2026

MSN Money - MSN

Apr 30, 2026

Apr 29, 2026

Could Dyne Therapeutics (DYN) Turn Its FORCE Platform Into a Broader Neurology Franchise? - simplywall.st

Apr 29, 2026

Apr 29, 2026

Dyne Therapeutics earnings up next: DMD launch path in focus By Investing.com - Investing.com India

Apr 29, 2026

Apr 29, 2026

Dyne Therapeutics earnings up next: DMD launch path in focus - Investing.com

Apr 29, 2026

Apr 29, 2026

Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart

Apr 29, 2026

Apr 29, 2026

Facioscapulohumeral Muscular Dystrophy Market: Pharma - openPR.com

Apr 29, 2026

Apr 28, 2026

DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 28, 2026

Apr 28, 2026

Director at Dyne Therapeutics (DYN) makes bona fide gift of 53,625 shares - Stock Titan

Apr 28, 2026

Apr 28, 2026

Dyne Therapeutics Insider Sold Shares Worth $7,101,120, According to a Recent SEC Filing - marketscreener.com

Apr 28, 2026

Apr 27, 2026

Dyne therapeutics director Jason Rhodes sells $7.1m in stock By Investing.com - Investing.com South Africa

Apr 27, 2026

Apr 27, 2026

Dyne Therapeutics(DYN.US) Director Sells US$7.1 Million in Common Stock - Moomoo

Apr 27, 2026

Apr 27, 2026

Dyne therapeutics director Jason Rhodes sells $7.1m in stock - Investing.com

Apr 27, 2026

Apr 27, 2026

[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity - Stock Titan

Apr 27, 2026

Apr 27, 2026

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting - The Manila Times

Apr 27, 2026

Apr 27, 2026

[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan

Apr 27, 2026

Apr 27, 2026

Dyne Therapeutics Announces Upcoming Presentation - GlobeNewswire

Apr 27, 2026

Apr 26, 2026

Dyne Therapeutics (DYN) Stifel 2026 Virtual CNS Forum Summary - Quartr

Apr 26, 2026

Apr 26, 2026

Dyne Therapeutics (DYN) Proxy filing Summary - Quartr

Apr 26, 2026

Apr 26, 2026

Dyne Therapeutics (DYN) TD Cowen 46th Annual Health Care Conference Summary - Quartr

Apr 26, 2026

Apr 23, 2026

Dyne Therapeutics director Kersten sells $219k in company stock - Investing.com

Apr 23, 2026

Apr 23, 2026

Dyne Therapeutics director Kersten sells $219k in company stock By Investing.com - Investing.com India

Apr 23, 2026

Apr 23, 2026

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network

Apr 23, 2026

Apr 23, 2026

[ARS] Dyne Therapeutics, Inc. SEC Filing - Stock Titan

Apr 23, 2026

Apr 23, 2026

Director-affiliated fund trims Dyne Therapeutics (DYN) stake in 10b5-1 sales - Stock Titan

Apr 23, 2026

Apr 23, 2026

Dyne Therapeutics (NASDAQ: DYN) sets 2026 virtual meeting, share increase vote - Stock Titan

Apr 23, 2026

Apr 23, 2026

Dyne used stock awards to hire 18 employees, covering 423,000 shares - Stock Titan

Apr 23, 2026

Apr 22, 2026

Jason Rhodes Sells 274,297 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock - MarketBeat

Apr 22, 2026

Apr 22, 2026

Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 272,049 Shares of Stock - MarketBeat

Apr 22, 2026

Apr 22, 2026

Dyne therapeutics director Jason Rhodes sells $16.48m in shares By Investing.com - Investing.com South Africa

Apr 22, 2026

Apr 22, 2026

Dyne Therapeutics(DYN.US) Director Sells US$16.48 Million in Common Stock - Moomoo

Apr 22, 2026

Apr 22, 2026

Atlas Venture funds sell Dyne (DYN) shares under 10b5-1 plan - Stock Titan

Apr 22, 2026

Apr 21, 2026

Dyne therapeutics director Dirk Kersten sells $6.8m in shares By Investing.com - Investing.com Australia

Apr 21, 2026

Apr 21, 2026

Dyne therapeutics director Dirk Kersten sells $6.8m in shares - Investing.com UK

Apr 21, 2026

Apr 21, 2026

DYN (Nasdaq) Form 144: Atlas Venture groups report proposed sales totaling tens of thousands of shares - Stock Titan

Apr 21, 2026

Apr 21, 2026

Atlas Venture affiliates sell shares of DYN (Nasdaq: DYN) in Rule 144 notices - Stock Titan

Apr 21, 2026

Apr 21, 2026

Atlas Venture sells DYN stock (Nasdaq: DYN) — 142,571-share entry listed - Stock Titan

Apr 21, 2026

Apr 21, 2026

Atlas Venture entities sell DYN shares (NASDAQ: DYN) under Form 144 disclosure - Stock Titan

Apr 21, 2026

Apr 21, 2026

Director-linked fund trims 337K Dyne Therapeutics (DYN) shares under 10b5-1 plan - Stock Titan

Apr 21, 2026

Apr 21, 2026

H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $50 - Moomoo

Apr 21, 2026

Apr 21, 2026

Dyne Therapeutics: De-Risked DMD Opportunity, Pivotal DM1 Readout, and Emerging M&A Appeal Support Buy Rating - TipRanks

Apr 21, 2026

Apr 21, 2026

H.C. Wainwright reiterates Dyne Therapeutics stock rating at buy By Investing.com - Investing.com Canada

Apr 21, 2026